Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker Buys 500,000 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker bought 500,000 shares of the stock in a transaction on Monday, December 16th. The shares were acquired at an average cost of $15.34 per share, for a total transaction of $7,670,000.00. Following the purchase, the director now owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This represents a 5.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, December 13th, Bros. Advisors Lp Baker bought 985,397 shares of Bicycle Therapeutics stock. The shares were bought at an average cost of $13.76 per share, with a total value of $13,559,062.72.

Bicycle Therapeutics Trading Up 0.1 %

BCYC opened at $15.14 on Wednesday. The stock’s 50 day simple moving average is $22.62 and its 200-day simple moving average is $22.71. The stock has a market cap of $1.05 billion, a PE ratio of -4.60 and a beta of 0.86. Bicycle Therapeutics plc has a 1 year low of $12.17 and a 1 year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. The firm’s revenue for the quarter was down 50.0% on a year-over-year basis. Equities analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Bicycle Therapeutics by 79.3% in the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock valued at $868,000 after acquiring an additional 16,958 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after purchasing an additional 5,310 shares during the last quarter. State Street Corp increased its stake in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after buying an additional 60,399 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Bicycle Therapeutics by 1,438.1% in the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after acquiring an additional 841,299 shares during the last quarter. Finally, HighVista Strategies LLC lifted its position in shares of Bicycle Therapeutics by 9.7% during the third quarter. HighVista Strategies LLC now owns 139,544 shares of the company’s stock worth $3,158,000 after purchasing an additional 12,289 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BCYC shares. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Finally, Stephens began coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $36.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.